A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of Icotinib in Patients With Advanced Cancers
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2014
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 30 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 04 Jun 2014 Planned initiation date changed from 1 May 2014 to 1 Jun 2014, as per ClinicalTrials.gov record.
- 07 May 2014 Planned initiation date changed from 1 Jan 2014 to 1 May 2014, as per ClinicalTrials.gov record.